252 related articles for article (PubMed ID: 26602014)
21. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
[TBL] [Abstract][Full Text] [Related]
22. Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer.
Hietanen T; Hakala T; Baltina D; Johansson R; Numminen S; Helle L; Valavaara R; Thölix E
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):37-40. PubMed ID: 9165505
[TBL] [Abstract][Full Text] [Related]
23. Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature.
Bus PJ; Verspaget HW; van Krieken JH; de Roos A; Keizer HJ; Bemelman WA; Vasen HF; Lamers CB; Griffioen G
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1179-83. PubMed ID: 10524651
[TBL] [Abstract][Full Text] [Related]
24. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
25. Toremifene citrate (Fareston).
Gerken P
Clin J Oncol Nurs; 2004 Oct; 8(5):529-30. PubMed ID: 15565747
[No Abstract] [Full Text] [Related]
26. Toremifene decreases type I, type II and increases type III receptors in desmoid and fibroma and inhibits TGFbeta1 binding in desmoid fibroblasts.
Stabellini G; Balducci C; Lilli C; Marinucci L; Becchetti E; Carinci F; Calastrini C; Dolci C; Lumare E; Locci P
Biomed Pharmacother; 2008 Sep; 62(7):436-42. PubMed ID: 18155395
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and secretion of transforming growth factor-beta1 by human desmoid fibroblast cell line and its modulation by toremifene.
Locci P; Bellocchio S; Lilli C; Marinucci L; Cagini L; Baroni T; Giustozzi G; Balducci C; Becchetti E
J Interferon Cytokine Res; 2001 Nov; 21(11):961-70. PubMed ID: 11747628
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
[TBL] [Abstract][Full Text] [Related]
29. [A case of lung and pleural metastases from breast cancer responding to toremifene].
Inoue K; Tabei T; Kusawake T; Sugamata N; Suemasu K; Higashi Y; Kurosumi M
Gan To Kagaku Ryoho; 2001 Feb; 28(2):221-4. PubMed ID: 11242650
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
31. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene.
Tonelli F; Ficari F; Valanzano R; Brandi ML
Tumori; 2003; 89(4):391-6. PubMed ID: 14606641
[TBL] [Abstract][Full Text] [Related]
32. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.
Ellmén J; Werner D; Hakulinen P; Keiling R; Fargeot P; Falkson G; Bezwoda WR
Cancer Chemother Pharmacol; 2000; 45(5):402-8. PubMed ID: 10803924
[TBL] [Abstract][Full Text] [Related]
33. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Zanchetta E; Ciniselli CM; Bardelli A; Colombo C; Stacchiotti S; Baldi GG; Provenzano S; Bertulli R; Bini F; Casale A; Greco FG; Ferrari A; Verderio P; Fiore M; Gronchi A; Casali PG; Morosi C; Palassini E
Cancer Med; 2021 Jul; 10(13):4356-4365. PubMed ID: 34102009
[TBL] [Abstract][Full Text] [Related]
34. Toremifene. where do we stand?
Mäenpää J; Holli K; Pasanen T
Eur J Cancer; 2000 Sep; 36 Suppl 4():S61-2. PubMed ID: 11056322
[TBL] [Abstract][Full Text] [Related]
35. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.
Wiseman LR; Goa KL
Drugs; 1997 Jul; 54(1):141-60. PubMed ID: 9211086
[TBL] [Abstract][Full Text] [Related]
36. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.
Skapek SX; Ferguson WS; Granowetter L; Devidas M; Perez-Atayde AR; Dehner LP; Hoffer FA; Speights R; Gebhardt MC; Dahl GV; Grier HE;
J Clin Oncol; 2007 Feb; 25(5):501-6. PubMed ID: 17290057
[TBL] [Abstract][Full Text] [Related]
37. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
Yamamoto Y; Kawazoe T; Iwase H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
[TBL] [Abstract][Full Text] [Related]
38. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M; Hayes DF; Ellmén J; Vuorinen J
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):29-36. PubMed ID: 9165504
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
40. Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Gounder MM; Lefkowitz RA; Keohan ML; D'Adamo DR; Hameed M; Antonescu CR; Singer S; Stout K; Ahn L; Maki RG
Clin Cancer Res; 2011 Jun; 17(12):4082-90. PubMed ID: 21447727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
